Status:
UNKNOWN
Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
Non-proliferative Diabetic Retinopathy
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
PHASE3
Brief Summary
In this randomized clinical trial, 100 eyes with nonproliferative diabetic retinopathy will be included and divided randomly into 2 groups: Intravitreal Bevacizumab group (50 eyes) that receive 6 bimo...
Eligibility Criteria
Inclusion
- Presence of severe NPDR with DRSS score more than 53 with or without diabetic macular edema
- Diagnosis of DM (type 1 or 2) with age more than 18 years' old
- Visual acuity from 20/25 to 20/40 according to Snellen chart examination or more than 69 letters according to ETDRS chart
Exclusion
- Presence of proliferative diabetic retinopathy features including vitreous hemorrhage or optic disc or retinal neovascularization
- History of retinal laser photocoagulation
- Tractional retinal detachment involving the macula
- Evidence of neovascularization of angle on examination
- Macular edema due to a cause other than DME
- Any ocular condition which may change visual acuity during the study
- History of intravitreal injection of anti-vascular endothelial growth factor agent in past 3 months
- History of any use of intravitreal corticosteroid
- History of major intra-ocular surgery except cataract surgery in the past 6 months
- History of thromboembolic every in the past 3 months
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04511715
Start Date
September 1 2020
End Date
November 1 2021
Last Update
August 13 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.